Article
Biochemistry & Molecular Biology
Takuma Hayashi, Ikuo Konishi
Summary: Through cancer genome testing, a germline pathogenic variant of the KIT gene was detected in a 32-year-old male patient with advanced GISTs, confirming the diagnosis of familial multinodular GIST. Treatment with imatinib resulted in long-term regression of GISTs in this patient. Therefore, cancer genome testing can be used to diagnose malignant tumors and select new therapeutic agents for advanced malignancies.
Review
Oncology
Hyunjee. V. V. Kwak, Katherine. J. J. Tardy, Andrew Allbee, Kristen Stashek, Ronald. P. P. DeMatteo
Summary: Gastrointestinal stromal tumor (GIST) is usually caused by sporadic mutations in the KIT or PDGFRA genes, but can also be caused by germline mutations. Surgical resection is critical for patients with germline GIST, especially in the stomach, since most tumors do not respond to tyrosine kinase inhibitors. However, there are no formal guidelines for timing or extent of surgical resection. This article discusses the challenges and principles of surgery in patients with germline GIST, with a case study of a patient harboring a germline KIT 579 deletion.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Jian Li, Xinhua Zhang, Yanhong Deng, Xin Wu, Zhichao Zheng, Yongjian Zhou, Shirong Cai, Yanqiao Zhang, Jun Zhang, Kaixiong Tao, Yuehong Cui, Hui Cao, Kuntang Shen, Jiren Yu, Ye Zhou, Wenxiao Ren, Chenglin Qu, Wanqi Zhao, Jin Hu, Wei Wang, Jason Yang, Lin Shen
Summary: This study evaluated the safety and antineoplastic activity of Avapritinib in Chinese patients with unresectable/metastatic gastrointestinal stromal tumors. The results showed that Avapritinib had remarkable efficacy in patients with PDGFRA D842V mutations and notable efficacy as fourth- or later-line monotherapy.
Article
Biochemistry & Molecular Biology
Chao Li, Zhishuang Gao, Zhiwei Cui, Zonghang Liu, Yibo Bian, Haoyu Sun, Nuofan Wang, Zhongyuan He, Bowen Li, Fengyuan Li, Zheng Li, Linjun Wang, Diancai Zhang, Li Yang, Zekuan Xu, Hao Xu
Summary: In this study, it was found that nanosized exosomes released from imatinib-resistant GISTs transmitted imatinib resistance to sensitive tumor cells. Through iTRAQ technology, it was also discovered that Ras-related protein Rab-35 (Rab35) was upregulated in imatinib-resistant GISTs. Further experiments showed that the ubiquitin-proteasome system and the deubiquitylating enzyme USP32 played a key role in regulating Rab35 expression and proteasomal degradation. Additionally, it was demonstrated that the transcription factor ETV1 promoted USP32 expression. Overall, the study provides insights into the mechanism of exosome-mediated drug resistance in GISTs as well as a potential target for intervention.
Review
Oncology
Jordan Senchak, Katya Ahr, Margaret von Mehren
Summary: This review focuses on the management of GIST with KIT and PDGFRA mutations, providing recommendations for TKI therapy based on mutation status. Avapritinib is the preferred TKI for patients with PDGFRA D842V mutation. Biopsies and ctDNA testing play important roles in guiding treatment decisions.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
J. R. Brown, B. Eichhorst, P. Hillmen, W. Jurczak, M. Kazmierczak, N. Lamanna, S. M. O'Brien, C. S. Tam, L. Qiu, K. Zhou, M. Simkovic, J. Mayer, A. Gillespie-Twardy, A. Ferrajoli, P. S. Ganly, R. Weinkove, S. Grosicki, A. Mital, T. Robak, A. Osterborg, H. A. Yimer, T. Salmi, M. -D. -Y. Wang, L. Fu, J. Li, K. Wu, A. Cohen, M. Shadman
Summary: In a multinational phase 3 trial, zanubrutinib was found to be superior to ibrutinib in treating relapsed or refractory CLL or SLL, with better efficacy and fewer side effects.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Immunology
Yu-Xiang Ma, Fu-Rong Liu, Yang Zhang, Qun Chen, Zhi-Qiang Chen, Qian-Wen Liu, Yan Huang, Yun-Peng Yang, Wen-Feng Fang, Ning Xi, Ning Kang, Yu-Lei Zhuang, Qi Zhang, Ying-Zhi Jiang, Li Zhang, Hong-Yun Zhao
Summary: CT053PTSA is a novel tyrosine kinase inhibitor that shows promising antitumor and antiangiogenic activity. The first-in-human study demonstrated that CT053PTSA is well tolerated and has a satisfactory safety profile. Further clinical trials are ongoing to evaluate the clinical activity of CT053PTSA.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Thomas L. Sutton, Brett S. Walker, Kevin G. Billingsley, Christopher L. Corless, Brett C. Sheppard, Michael C. Heinrich, Skye C. Mayo
Summary: This study aimed to evaluate predictors of 10-year metastatic survivorship in patients with gastrointestinal stromal tumors (GIST) treated with tyrosine kinase inhibitor therapy. The results showed that 10-year survivorship is achievable in GIST patients in the era of tyrosine kinase inhibitors, and it is associated with younger age and longer time to first progression.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Review
Pathology
Josephine K. Dermawan, Brian P. Rubin
Summary: This review discusses the molecular pathogenesis of gastrointestinal stromal tumors (GISTs), including the identification of primary activating driver mutations and targeted therapies. It highlights GIST's role as a paradigm for personalized medicine.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE
(2022)
Article
Oncology
Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Simkovic, Jiri Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak
Summary: The study compared the efficacy and safety of zanubrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. The results showed that zanubrutinib had better outcomes in terms of efficacy, atrial fibrillation rate, and cardiac safety compared to ibrutinib.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Sawako Uchida-Kobayashi, Ken Kageyama, Akira Yamamoto, Hiroko Ikenaga, Kanako Yoshida, Kohei Kotani, Kenjiro Kimura, Naoshi Odagiri, Atsushi Hagihara, Hideki Fujii, Masaru Enomoto, Akihiro Tamori, Shoji Kubo, Yukio Miki, Norifumi Kawada
Summary: In patients with unresectable HCC treated with lenvatinib, tumor-related hemorrhages can occur, especially in cases with larger tumors. The dosing period and survival time of patients with hemorrhage were significantly shorter compared to those without hemorrhage. Furthermore, despite the quick suppression of tumor blood flow by lenvatinib, tumor hemorrhage can still happen possibly due to blockade of feeding circulation.
Article
Hematology
John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Jennifer R. Brown, Talha Munir, Anthony Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach
Summary: ELEVATE-RR trial showed that acalabrutinib has noninferior progression-free survival and lower incidence of key adverse events compared to ibrutinib in previously treated chronic lymphocytic leukemia patients. Post hoc analysis further characterized the adverse events of acalabrutinib and ibrutinib. It was found that acalabrutinib had higher incidence rates of headache and cough, while ibrutinib had higher rates of diarrhea, joint pain, urinary tract infection, back pain, muscle spasms, and dyspepsia. Ibrutinib also had higher rates of atrial fibrillation/flutter, hypertension, and bleeding. The discontinuation rate due to adverse events was lower with acalabrutinib. The overall event-based analyses and adverse event burden scores demonstrated that ibrutinib had a higher burden of adverse events compared to acalabrutinib, particularly in atrial fibrillation, hypertension, and bleeding.
Article
Oncology
Ji Hyun Lee, Su-Jin Shin, Eun-Ah Choe, Jungyoun Kim, Woo Jin Hyung, Hyo Song Kim, Minkyu Jung, Seung-Hoon Beom, Tae Il Kim, Joong Bae Ahn, Hyun Cheol Chung, Sang Joon Shin
Summary: This study analyzed the incidence of NTRK fusion in KIT/PDGFRA wild-type GISTs and found that 16% of cases in the Yonsei Cancer Center had NTRK fusion. The confirmation of NTRK fusion in KIT/PDGFRA wild-type GISTs provides important information for improving therapeutic outcomes and suggests further research to improve methods for identifying this disease subtype.
Review
Public, Environmental & Occupational Health
Mingyang Feng, Yang Yang, Weiting Liao, Qiu Li
Summary: This systematic review aimed to analyze the cost-effectiveness of tyrosine kinase inhibitors (TKIs) in the treatment of gastrointestinal stromal tumors (GIST). The results showed that TKIs were cost-effective for both advanced and resectable GIST, and individualized TKI treatment based on precision medicine was more cost-effective than empirical treatment.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Oncology
Prahathishree Mohanavelu, Mira Mutnick, Nidhi Mehra, Brandon White, Sparsh Kudrimoti, Kaci Hernandez Kluesner, Xinyu Chen, Tim Nguyen, Elaina Horlander, Helena Thenot, Vamsi Kota, Cassie S. Mitchell
Summary: Frontline therapy for BCR-ABL (Ph+) chronic myeloid leukemia (CML) involves tyrosine kinase inhibitors (TKIs) treatment. A systematic meta-analysis comparing the incidence of gastrointestinal adverse events (GI AEs) in a large heterogeneous CML population as a function of TKI type showed significant differences in GI AE profiles between different TKIs but minimal differences in patient survival. Optimal TKI selection for chronic phase CML patients without resistant mutations should consider the TKI AE profile, comorbidities, and lifestyle.
Article
Food Science & Technology
Phatcharaporn Budluang, Pornsiri Pitchakarn, Pisamai Ting, Piya Temviriyanukul, Ariyaphong Wongnoppawich, Arisa Imsumran
FOOD SCIENCE & NUTRITION
(2017)
Article
Oncology
Yasushi Adachi, Rong Li, Hiroyuki Yamamoto, Yongfen Min, Wenhua Piao, Yu Wang, Arisa Imsumran, Hua Li, Yoshiaki Arimura, Choon-Taek Lee, Kohzoh Imai, David P. Carbone, Yasuhisa Shinomura
Article
Gastroenterology & Hepatology
Yu Wang, Yasushi Adachi, Arisa Imsumran, Hiroyuki Yamamoto, Wenhua Piao, Hua Li, Masanori Ii, Yoshiaki Arimura, Mi Young Park, Dalrae Kim, Choon-Taek Lee, David P. Carbone, Kohzoh Imai, Yasuhisa Shinomura
JOURNAL OF GASTROENTEROLOGY
(2010)
Article
Chemistry, Medicinal
Wirote Tuntiwechapikul, Thanachai Taka, Chonnipa Songsomboon, Navakoon Kaewtunjai, Arisa Imsumran, Luksana Makonkawkeyoon, Wilart Pompimon, T. Randall Lee
JOURNAL OF MEDICINAL FOOD
(2010)
Article
Oncology
Yasushi Adachi, Hirokazu Ohashi, Arisa Imsumran, Hiroyuki Yamamoto, Yasutaka Matsunaga, Hiroaki Taniguchi, Katsuhiko Nosho, Hiromu Suzuki, Yasushi Sasaki, Yoshiaki Arimura, David P. Carbone, Kohzoh Imai, Yasuhisa Shinomura
Article
Oncology
Nahathai Dukaew, Kongthawat Chairatvit, Pornsiri Pitchakarn, Arisa Imsumran, Jirarat Karinchai, Wirote Tuntiwechapikul, Ariyaphong Wongnoppavich
Article
Plant Sciences
Jirarat Karinchai, Phatcharaporn Budluang, Piya Temviriyanukul, Pisamai Ting, Onanong Nuchuchua, Ariyaphong Wongnoppavich, Arisa Imsumran, Pornsiri Pitchakarn
Summary: This study demonstrated that the hydrophilic fractions of AB exhibit anti-inflammatory activity in LPS-stimulated macrophages. The mechanism used by the AB involves the scavenging of free radicals and the reduction of proinflammatory mediators, including IL-1 beta, IL-6, TNF-alpha, NO, iNOS and COX-2.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)
Article
Nutrition & Dietetics
Pensiri Buacheen, Angkana Chaipuang, Jirarat Karinchai, Onanong Nuchuchua, Arisa Imsumran, Ariyaphong Wongnoppavich, Nuttaporn Pimpha, Pornsiri Pitchakarn
Summary: This study found that the ethanolic extract of Anoectochilus burmannicus (ABE) can be used as a reducing agent and stabilizer for nano-selenium (SeNP) synthesis. ABE-SeNPs had higher antioxidant activity compared to SeNPs, while ABE-SeNPs (4 µM Se) exhibited stronger anti-inflammatory activity in LPS-induced macrophages. ABE acted as a stabilizer for SeNPs, preventing particle aggregation and preserving antioxidant activity even after long-term storage.
Article
Multidisciplinary Sciences
Pensiri Buacheen, Jirarat Karinchai, Natchapon Kammasit, Piya Temviriyanukul, Chutikarn Butkinaree, Santi Watthana, Ariyaphong Wongnoppavich, Arisa Imsumran, Pornsiri Pitchakarn
Summary: This study found that Anoectochilus burmannicus ethanolic extract (ABE) and kinsenoside (Kin) had significant inhibitory effects on benzyl butyl phthalate (BBP) and bisphenol A (BPA) induced adipogenesis, with different modulations on adipogenic gene expression. This finding not only supports the health benefits of this plant for people exposed to obesogens, but also provides motivation for the conservation and culture of this orchid for development as an economic plant and healthy food.
SCIENTIFIC REPORTS
(2023)
Article
Chemistry, Multidisciplinary
Manaschanok Lailerd, Thiri Wai Linn, Narissara Lailerd, Duangporn Amornlerdpison, Arisa Imsumran
Summary: This study investigated the effects of Carissa carandas fruit extract on inflammation and insulin resistance in vitro and in vivo. The results showed that the extract reduced inflammation and improved insulin resistance in cellular and animal models. It also significantly improved glycemic control and protected against pancreatic damage in diabetic rats.
APPLIED SCIENCES-BASEL
(2023)
Article
Chemistry, Multidisciplinary
Navakoon Kaewtunjai, Rawiwan Wongpoomchai, Arisa Imsumran, Wilart Pompimon, Anan Athipornchai, Apichart Suksamrarn, T. Randall Lee, Wirote Tuntiwechapikul
Article
Oncology
Arisa Imsumran, Yasushi Adachi, Hiroyuki Yamamoto, Rong Li, Yu Wang, Yongfen Min, Wenhua Piao, Katsuhiko Nosho, Yoshiaki Arimura, Yasuhisa Shinomura, Masao Hosokawa, Choon-Taek Lee, David P. Carbone, Kohzoh Imai
Article
Oncology
Yoon-Jin Lee, Arisa Imsumran, Mi-Young Park, Sung-Youn Kwon, Ho Il Yoon, Jae-Ho Lee, Chul-Gyu Yoo, Young Whan Kim, Sung Koo Han, Young-Soo Shim, Wenhua Piao, Hiroyuki Yamamoto, Yasushi Adachi, David P. Carbone, Choon-Taek Lee
Article
Gastroenterology & Hepatology
Y Min, Y Adachi, H Yamamoto, A Imsumran, Y Arimura, T Endo, Y Hinoda, CT Lee, S Nadaf, DP Carbone, K Imai